scholarly journals Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score?

2016 ◽  
Vol 177 (2) ◽  
pp. 319-320 ◽  
Author(s):  
Hugo J. A. Adams ◽  
Thomas C. Kwee
Keyword(s):  
Fdg Pet ◽  
Prognostic Value ◽  
End Of Treatment ◽  
Pre Treatment

scholarly journals Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis

PLoS ONE ◽  
2018 ◽  
Vol 13 (3) ◽  
pp. e0194435 ◽  
Author(s):  
Hongxi Wang ◽  
Guohua Shen ◽  
Chong Jiang ◽  
Li Li ◽  
Futao Cui ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
Meta Analysis ◽  
Natural Killer T Cell ◽  
End Of Treatment ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Killer T Cell

Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas

2011 ◽  
Vol 107 (3) ◽  
pp. 527-535 ◽  
Author(s):  
Cécile Colavolpe ◽  
Philippe Metellus ◽  
Julien Mancini ◽  
Maryline Barrie ◽  
Céline Béquet-Boucard ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Prognostic Value ◽  
High Grade ◽  
High Grade Gliomas ◽  
Pre Treatment

Prognostic value of pre-treatment 18F-FDG-PET uptake in small-cell lung cancer

2017 ◽  
Vol 31 (6) ◽  
pp. 462-468 ◽  
Author(s):  
Meryem Aktan ◽  
Mehmet Koc ◽  
Gul Kanyilmaz ◽  
Berrin Benli Yavuz
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Small Cell ◽  
Small Cell Lung ◽  
18F Fdg ◽  
Pre Treatment

scholarly journals Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review

2015 ◽  
Vol 95 (1) ◽  
pp. 11-18 ◽  
Author(s):  
Hugo J. A. Adams ◽  
Rutger A. J. Nievelstein ◽  
Thomas C. Kwee
Keyword(s):  
Systematic Review ◽  
Follicular Lymphoma ◽  
Fdg Pet ◽  
Prognostic Value ◽  
End Of Treatment

scholarly journals Additional Value of 2-[18F]FDG PET/CT Comparing to MRI in Treatment Approach of Anal Cancer Patients

2020 ◽  
Vol 9 (9) ◽  
pp. 2715
Author(s):  
Reyhaneh Manafi-Farid ◽  
Alexander Kupferthaler ◽  
Helwig Wundsam ◽  
Georg Gruber ◽  
Reza Vali ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Anal Cancer ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Number Of Patients ◽  
Pet Ct ◽  
18F Fdg ◽  
Pre Treatment ◽  
Fdg Pet Ct ◽  
The Impact

Accurate staging and treatment planning are imperative for precise management in Anal Cancer (ACa) patients. We aimed to evaluate the additive and prognostic value of pre-treatment 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (2-[18F]FDG PET/CT) in the staging and management of ACa compared to magnetic resonance imaging (MRI). This retrospective study was conducted on 54 patients. Pre-treatment 2-[18F]FDG PET/CT studies and MRI reports were compared considering the primary tumor, pelvic lymph nodes, and metastatic lesions. The impact of 2-[18F]FDG PET/CT in the management and its prognostic value, using maximum standardized uptake value (SUVmax), were assessed. Discordant findings were found in 46.3% of patients (5 in T; 1 in T and N; 18 in N; and 1 in M stage). 2-[18F]FDG PET/CT resulted in up-staging in 9.26% and down-staging in 3.7% of patients. Perirectal lymph nodes were metabolically inactive in 12.9% of patients. Moreover, 2-[18F]FDG PET/CT resulted in management change in 24.1% of patients. Finally, SUVmax provided no prognostic value. 2-[18F]FDG PET/CT altered staging and management in a sizable number of patients in this study, and supports a need for a change in guidelines for it to be used as a routine complementary test in the initial management of ACa.

scholarly journals Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 3003-3003 ◽  
Author(s):  
Enrico Derenzini ◽  
Angela Gueli ◽  
Safaa Ramadan ◽  
Anna Vanazzi ◽  
Simona Sammassimo ◽  
...  
Keyword(s):  
T Cell ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
T Cell Lymphomas ◽  
End Of Treatment

Abstract T-cell lymphomas represent a rare and heterogeneous group of non-Hodgkin lymphomas (NHLs) characterized by dismal prognosis. Current first line chemotherapeutic approaches have not significantly changed during the last 20 years, and several efforts have been made for early risk stratification of T-cell NHL patients with unsatisfactory results. Functional imaging with 2-deoxy-2-[fluorine-18]fluoro- D-glucose positron emission tomography scan (FGD-PET) has demonstrated improved outcome stratification and response evaluation in Hodgkin lymphoma and B-cell NHL, in comparison with computed tomography (CT) scan. Most T-cell lymphomas are FDG avid and FDG-PET is routinely used in clinical practice, however limited and conflicting data are available on the value of FDG-PET in response assessment at the end of treatment (FDG-PETend). With the aim of evaluating the prognostic value of FDG-PETend in T-cell lymphomas we performed a retrospective study evaluating all T-cell NHL patients treated at the European Institute of Oncology (IEO, Milan) over the past 20 years. Clinical data of all T-cell NHL patients treated at IEO from 1995 to 2015 were retrospectively collected. The back bone of first line therapy did not significantly change over time, being based on the administration of CHOP/CHOP-like chemotherapy eventually followed by treatment intensification with autologous stem cell transplantation (ASCT). Post first-line therapy FDG-PET scans were visually evaluated according to the criteria of the international Harmonization Project (positive vs negative). Ninety-eight consecutive patients (58 males, 40 females) with complete clinical data were considered in this analysis. FDG-PET was used for response evaluation starting from 2002, but only 18 patients considered in the present analysis were treated before 2002. Median age at diagnosis was 54 years (range 14-82). Fifty-two patients (53.1%) had Peripheral T-cell lymphomas not otherwise specified (PTCL-NOS), 23 (23.5%) had anaplastic large T-cell lymphoma (ALCL), 15 (15.3%) had acute lymphoblastic T-cell lymphoma (LAL-T), 8 (8.1%) had NK/T-cell lymphoma. Ten patients were diagnosed in stage I, 21 in stage II, 17 in stage III, 50 patients in stage IV. Thirty-two patients underwent ASCT during the study period. Median follow-up was 16 months (range 1-182). 42 patients were evaluated with FDG-PET at the end of first line therapy: 25 had negative (60%), and 17 (40%) positive PET scans. In 56 patients response was evaluated with CT scan only, and complete responses or complete responses unconfirmed (CR/CRu) were detected in 29 cases (51%). The 10-year progression free survival (PFS) and overall survival (OS) of the whole patient cohort were 22% and 32% respectively. To determine the prognostic value of FDG-PETend we first assessed the PFS of PET positive vs PET negative patients. Those patients who were PET positive at the end of treatment had a statistically inferior PFS compared to PET negative ones (5-year PFS: 29% vs 47% respectively; p<0.01). These data indicate that although a negative PET after initial therapy is a good prognostic predictor, about half of all patients still relapse after achievement of a negative PET. To better define the prognostic value of FDG-PETend scan in T-cell lymphomas, we restricted our analysis to those patients who obtained a CR after first line therapy, comparing the outcome of PET negative patients (n=25) with the outcome of patients who did not have a PET scan but were deemed in CR after a negative CT scan (n=17). Interestingly we did not observe significant differences between the 2 groups (5-year PFS was 47% in both groups). These data were also confirmed when the analysis was restricted to the PTCL-NOS and ALCL subgroups, suggesting unsatisfactory improvements in the quality of CR assessment with a limited negative predictive value of negative PET scans after first line therapy. In conclusion, although our data confirm the prognostic value of end of treatment FDG-PET scan in T-cell lymphoma, they also highlight the limits of current prognostic stratification tools suggesting that different timing of response evaluation or alternative methods to detect minimal residual disease in those patients in CR after first line therapy are warranted. Disclosures No relevant conflicts of interest to declare.

scholarly journals PET2015UZ: Prognostic value of pre-treatment 18FDG-PET in operable breast cancer v1

2020 ◽  
Author(s):  
Vincent Vinh-Hung ◽  
Hendrik Everaert ◽  
Mark De Ridder
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Survival Data ◽  
Fdg Pet ◽  
Prognostic Value ◽  
18Fdg Pet ◽  
Prediction Of Survival ◽  
Node Ratio ◽  
Pre Treatment ◽  
Overall Survival Analysis

This retrospective-observational study hypothesizes that preoperative 18FDG-PET for breast cancer has significant prognostic value for the prediction of survival. Data from patients who had breast surgery and had a preoperative FDG-PET examination at the UZ Brussel in 2002-2008 and in 2009-2015 will be analyzed without restriction on age or sex. Data collection for the cohort 2002-2008 has been finalized and will be shared on Mendeley (Reserved DOI: 10.17632/sfvtmrd8z9.1 ). Data for the cohort 2009-2015 will be collected by end of 2020. Detailed and referred to in: # Breast cancer preoperative 18FDG-PET, overall survival prognostic separation compared with the lymph node ratio. # Vinh-Hung V, Everaert H, Gorobets O, Van Parijs H, Verfaillie G, Vanhoeij M, Storme G, Fontaine C, Lamote J, Perrin J, Farid K, Nguyen NP, Verschraegen C, De Ridder M. # Breast Cancer. 2021 Jul;28(4):956-968. doi: 10.1007/s12282-021-01234-z # PMID: 33689151 https://link.springer.com/article/10.1007%2Fs12282-021-01234-z # Is there a utility of [18F]FDG-PET before surgery in breast cancer? A 15-years overall survival analysis. # Perrin, Farid K, Van Parijs H, Gorobets O, Vinh-Hung V, Nguyen NP, Djassemi N, De Ridder M, Everaert H. # World J Clin Oncol. Pending. Study registration: https://www.isrctn.com/ISRCTN17962845

Sign in / Sign up

Export Citation Format

Share Document